Shawn Singh - Jun 23, 2025 Form 4 Insider Report for Vistagen Therapeutics, Inc. (VTGN)

Role
President and CEO, Director
Signature
/s/ Cynthia Anderson, Attorney-in-Fact
Stock symbol
VTGN
Transactions as of
Jun 23, 2025
Transactions value $
$0
Form type
4
Date filed
6/25/2025, 05:15 PM
Previous filing
Jul 2, 2024
Next filing
Jul 1, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Singh Shawn President and CEO, Director C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO /s/ Cynthia Anderson, Attorney-in-Fact 2025-06-25 0001412071

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VTGN Stock Option (Right to Buy) Award $0 +300K $0.00 300K Jun 23, 2025 Common Stock 300K $1.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Equity Omnibus Incentive Plan, as amended. The Options will begin vesting on June 23, 2025 (the "Grant Date"), and will vest in equal monthly installments over a three-year period until the Options become fully vested on the three (3) year anniversary of the Grant Date.